Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)

American Heart Journal

Volumn 153, Issue 6, 2007, Pages 960-969

  Brieger, David ^a   Van de Werf, Frans ^b   Avezum, Álvaro ^c   Montalescot, Gilles ^d   Kennelly, Brian M ^e   Granger, Christopher B ^f   Goodman, Shaun G ^g   Dabbous, Omar H ^h   Agnelli, Giancarlo ⁱ  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PYRIDINE DERIVATIVE; THIENOPYRIDINE; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEART INFARCTION; HUMAN; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT ELEVATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMORBIDITY; CORONARY DISEASE; DRUG INTERACTIONS; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REGISTRIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; SURVIVAL RATE; WARFARIN;

EID: 34249328047     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.03.035     Document Type: Article

References (23)

1. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337 (1997) 447-452
2. Boersma E., Akkerhuis K.M., Theroux P., et al. Platelet glycoprotein IIb/IIIa receptor inhibition in Non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 100 (1999) 2045-2048
3. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
4. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100 (1999) 1593-1601
5. Cohen M., Theroux P., Borzak S., et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 144 (2002) 470-477
6. Ferguson J.J., Antman E.M., Bates E.R., et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 146 (2003) 628-634
7. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
8. Blazing M.A., de Lemos J.A., White H.D., et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 292 (2004) 55-64
9. The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 141 (2001) 190-199
10. Eagle K.A., Lim M.J., Dabbous O.H., et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291 (2004) 2727-2733
11. Granger C.B., Goldberg R.J., Dabbous O., et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med 163 (2003) 2345-2353
12. Moscucci M., Fox K.A., Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1815-1823
13. Bertrand M.E., Simoons M.L., Fox K.A., et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the management of acute coronary syndromes of the European Society of Cardiology. Eur Heart J 23 (2002) 1809-1840
14. Fox K.A.A., Goodman S.G., Klein W., et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 23 (2002) 1177-1189
15. Borentain M., Montalescot G., Bouzamondo A., et al. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis. Catheter Cardiovasc Interv 65 (2005) 212-221
16. Montalescot G., Collet J.P., Tanguy M.L., et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110 (2004) 392-398
17. Fox K.A., Anderson Jr. F.A., Dabbous O.H., et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart 93 (2007) 177-182
18. Montalescot M., White H.D., Gallo R., et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) [in press]
19. Hulot J.S., Montalescot G., Lechat P., et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 77 (2005) 542-552
20. Lim W., Dentali F., Eikelboom J.W., et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144 (2006) 673-684
21. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
22. Yusuf S., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
23. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216